Uncategorized

[PLoS Biology] Researchers generated anti-CD22 antibody 1C5 that specifically inhibits ligand binding of CD22. Both Cd22−/− mice and mice treated with 1C5 show expansion of regulatory B cells in follicular B cells.

[Oncogene] Investigators identifed HILPDA as a tumor-intrinsic regulator of immune evasion in breast cancer. HILPDA overexpression increases the infiltration and suppressive activity of Tregs while decreasing the infiltration, activation, and cytotoxicity of CD8+ T cells and natural killer cells.

[Nature Communications] Using pancreatic islet transplantation in NOD mice, researchers showed that induction of tolerance to a CD4+ T cell hybrid insulin peptide neoepitope reprograms the fate of antigen-specific CD8+ T cells within the grafts.

[University of Texas MD Anderson Cancer Center] In recognition of their significant achievements to advance cancer care and immunology research, Drs. Theresa Guise and Stephanie Watowich have been elected fellows of the American Association for the Advancement of Science (AAAS).

[Immunity] The authors identified p16High immune cells as critical mediators of disease tolerance. They showed that the FDA-approved BNT162b2 mRNA COVID-19 vaccine rapidly induces p16High immune subsets in mice and humans.

[Nature Reviews Cancer] The authors explore current insights into the regulation and function of type I IFNs in cancer, with a particular focus on tumor-intrinsic mechanisms controlling canonical and chronic signaling.

[Nature Communications] Researchers showed that the X-linked histone demethylase 6 A (KDM6A) is essential for maintaining healthy cholesterol metabolism in the liver.

[Journal for Immunotherapy of Cancer] Investigators offered a novel strategy to enhance HCC immunotherapy by blocking nuclear factor erythroid 2-related factor 2 (Nrf2), which has the potential to address the low response rates observed with current HCC immunotherapies.

[BMC Medicine] Scientists investigated whether pharmacologic inhibition of MST3 could attenuate the initiation and progression of metabolic dysfunction-associated steatohepatitis-associated HCC in vivo.

[Cell Death & Disease] The authors identify T cell intracellular antigen 1 (TIA1) as a crucial hepatoprotective factor that attenuates metabolic dysfunction-associated steatotic liver disease progression by orchestrating stress granule-dependent translational control of Srebf1 mRNA.

[Alimentary Pharmacology & Therapeutics] Researchers identified independent risk factors of HCC after hepatitis B surface antigen seroclearance and developed and validated a risk prediction model.

[Journal of Ethnopharmacology] Scientists validated the molecular mechanism of albiflorin ALB against liver fibrosis, integrating both in vivo and in vitro experiments with molecular docking and molecular dynamics simulations.